1Garabrant DH, Dumas C. Epidemiology of organic solvents and connective tissue disease. Arthritis Res, 2000, 2: 5-15.
2Gutierrez J, Vergara MJ, Guerrero M, et al. Multiple sclerosis and human herpes virus 6. Infection, 2002, 30: 145-149.
3Chung L, Utz PJ. Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep, 2004, 6:156-163.
4Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum, 2001, 44: 1359-1362.
5Denton CP, Black CM. Scleroderma clinical and pathological advances. Best Pract Res Clin Rheumatol, 2004, 18: 271-290.
6Falkner D, Wilson J, Medsger TA, et al. HLA and clinical associations in systemic sclerosis with anti-Th/To antibodies. Arthritis Rheum, 1998, 41: 74-80.
7Lambert NC, Pang JM, Erickson TD, et al. Male microchimerism in women with systemic sclerosis and healthy women who never gave birth to a son. Ann Rheum Dis, 2004, 18: 845-848.
8Reveille JD. Antibodies to centromere and centriole in scleroderma spectrum disorders. J Clin Invest, 1992, 89: 1208-1213.
9Hu PQ, Fertig N, Medsger TA Jr. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol, 2004, 173: 2834.
10Hall HI, Jamison P, Fulton JP. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol, 2003,49: 624-630.
